Marina Barbosa da Silva

Marina Barbosa da Silva

Auto-generated profile, based on publicly available information

Marina Barbosa da Silva

Universidade do Oeste Paulista, Guarujá, Brazil

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2024 in Neurological Research
Verified
Journal Article
Closed access
MSMarina Barbosa da Silva
Marina Barbosa da Silva
DFDomênica Baroni Coelho de Oliveira Ferreira
Domênica Baroni Coelho de Oliveira Ferreira
CMCristian D. Mendieta
Cristian D. Mendieta
HSHamilcar Pereira da Silva
Hamilcar Pereira da Silva
LNLívia Aguiar Nogueira-Rosa
Lívia Aguiar Nogueira-Rosa
NMNathalia Moraes-Figueiredo
Nathalia Moraes-Figueiredo
Galcanezumab is a monoclonal antibody targeting the CGRP pathway and represents the latest disease-specific and mechanism-based therapeutic option for cluster headache (CH). We performed a systematic review and meta-analysis to evaluate the efficacy and safety of galcanezumab for CH. We searched PubMed, Embase, and Cochrane Library for studies implementing galcanezumab for episodic and chronic CH. We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and Reporting Guidelines for Meta-analyses of Observational Studies (MOOSE) guidelines. The primary outcome was efficacy, defined by a reduction from the baseline of at least 50% in the weekly frequency of CH attacks and the Patient Global Impression of Improvement scale (PGI-I). Secondary outcomes included treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs). A total of 504 patients were included from 6 studies, of which 2 were RCTs. The follow-up period ranged from 3 weeks to 15 months. The mean age was 44.4 ± 10.2 years, with 24.4% female patients. Overall efficacy was 76.0% (95% CI 0.67-0.85), TEAEs were observed in 48.0% of patients (95% CI 0.25-0.72), and the most common were nasopharyngitis, local injection pain, and local injection swelling. TEAEs were, however, considerably higher within the 300 mg dose group compared with the 240 mg dose group, 80.0% (95% CI 0.65-0.87) versus 28.0% (95% CI 0.12-0.47), respectively. This meta-analysis suggests that galcanezumab is effective in reducing the number of CH attacks and can be considered a safe medication.

20 May 2025 in Endocrine and Metabolic Science
Verified
Journal Article
Open access
MMMir Wajid Majeed
Mir Wajid Majeed
EFEmma Finnegan
Emma Finnegan
MRMariano Gallo Ruelas
Mariano Gallo Ruelas
MQMarco Quirós
Marco Quirós
MSMarina Barbosa da Silva
Marina Barbosa da Silva
MGMohammad Ashraf Ganie
Mohammad Ashraf Ganie

3 May 2025 in SN Comprehensive Clinical Medicine
Verified
Journal Article
Closed access
PDF file
AMAlice Campos Meneses
Alice Campos Meneses
FCFelipe Perlingeiro Picard Flores da Cunha
Felipe Perlingeiro Picard Flores da Cunha
FRFernanda Cristina Poscai Ribeiro
Fernanda Cristina Poscai Ribeiro
LBLucas de Deus Borges
Lucas de Deus Borges
SKSarah Beatriz da Silva Koch
Sarah Beatriz da Silva Koch
AFAracelle Victor Do Carmo Faria
Aracelle Victor Do Carmo Faria

27 September 2024 in Research Square
Verified
Preprint
Open access
PDF file
CMCristian Mendieta
Cristian Mendieta
MSMarina Barbosa Da Silva
Marina Barbosa Da Silva
LNLivia Aguiar Nogueira-Rosa
Livia Aguiar Nogueira-Rosa
DFDomênica Baroni Coelho de Oliveira Ferreira
Domênica Baroni Coelho de Oliveira Ferreira
JBJhon Bocanegra-Becerra
Jhon Bocanegra-Becerra
NFNathalia Moraes Figueiredo
Nathalia Moraes Figueiredo
Oxcarbazepine (OXC) has demonstrated comparable efficacy to Carbamazepine (CBZ) in the treatment of Trigeminal neuralgia (TN), with the added benefit of fewer adverse events (AEs). Whether it can be used as a substitute for carbamazepine is yet to be verified. To address this, we conducted a comprehensive meta-analysis, exploring efficacy and adverse events in detail. We searched PubMed, Embase, Cochrane Library, and Google Scholar for studies comparing CBZ to OXC in patients with TN. The main outcomes were efficacy, AEs, frequency of neurological AEs, skin reactions, and alterations in laboratory parameters. Statistical analysis was performed using Review Manager 5.4.1. And the risk of bias was assessed using RoB-2 and ROBINS-I. We included 838 patients from three observational studies and two randomized clinical trials (RCTs). CBZ was used to treat TN in 445 (53.1%) patients. The CBZ group when compared with the OXC group had no significant difference in efficacy (OR:0.58; 95% Cl:0.14-2.40; p=0.45). Both groups had significant differences noted in AEs, with higher frequency observed in the CBZ group (OR:2.30; 95% Cl:1.49-3.54; p=0.0002). Similarly, there was a significant difference in neurological AEs (OR:2.76; 95% Cl:1.53-4.87; p=0.0007). OXC and CBZ demonstrated similar efficacy in treating trigeminal neuralgia. However, the consideration of adverse events may favor clinical decision-making to OXC due to its superiority. Nonetheless, more randomized controlled trials (RCTs) are necessary to confirm this conclusion in the future

18 February 2025 in Brazilian Journal of Natural Sciences
Verified
Journal Article
Open access
PDF file
MBMarianne Carneiro Barone Bomfim
Marianne Carneiro Barone Bomfim
EFEnrico Vieira de Medeiros e Figueira
Enrico Vieira de Medeiros e Figueira
PTPedro Henrique Felix Tadei
Pedro Henrique Felix Tadei
SSSerena Pocas Moreno Silva
Serena Pocas Moreno Silva
MSMarina Barbosa da Silva
Marina Barbosa da Silva
APAdriana Pina
Adriana Pina
Introdução: A doação de medula óssea é um procedimento essencial para o tratamento de doenças hematológicas, como leucemias e linfomas. No entanto, a baixa adesão ao cadastro de doadores voluntários no Brasil, especialmente entre grupos estratégicos como estudantes de Medicina, reflete um possível déficit de conhecimento e conscientização sobre o tema. Objetivo: Avaliar o conhecimento dos estudantes de Medicina da cidade de Guarujá - SP sobre a doação de medula óssea, identificando lacunas informacionais e fatores que influenciam a disposição para o cadastro como doadores voluntários. Método: Estudo de corte transversal com abordagem quantitativa, realizado com 190 estudantes de Medicina de uma universidade particular da cidade de Guarujá – SP. Os dados foram coletados por meio de um questionário estruturado contendo questões sociodemográficas, conhecimento sobre o Registro Nacional de Doadores de Medula Óssea (REDOME), percepção do processo de doação e motivadores/barreiras para o cadastro. Os dados foram analisados de forma descritiva, com distribuição percentual das respostas. Resultados: Os achados revelaram que 56,84% dos estudantes desconheciam o REDOME e apenas 6,84% estavam cadastrados como doadores. Entre os principais motivos para não se cadastrarem estavam a falta de informação (37,89%) e o medo de complicações (23,68%). Apesar disso, 53,16% afirmaram já ter considerado a possibilidade de doar medula óssea. Barreiras emocionais e desinformação mostraram-se predominantes. A maioria dos estudantes era do sexo feminino (64,74%), entre 18 e 24 anos (78,42%) e solteira (69,47%). Conclusão: Os resultados evidenciam a necessidade de estratégias educativas voltadas ao público universitário da área da saúde, com inclusão do tema no currículo, campanhas informativas e facilitação do processo de cadastro. Tais medidas são essenciais para ampliar a base de doadores no país e fortalecer o papel dos futuros médicos na promoção da doação de medula óssea.